Compare GPRO & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GPRO | SPRO |
|---|---|---|
| Founded | 2004 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 154.6M | 135.5M |
| IPO Year | 2014 | 2017 |
| Metric | GPRO | SPRO |
|---|---|---|
| Price | $1.32 | $2.77 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 8.1M | 425.0K |
| Earning Date | 05-11-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 79.08 | ★ 111.81 |
| EPS | N/A | ★ 0.15 |
| Revenue | ★ $651,542,000.00 | $66,802,000.00 |
| Revenue This Year | $23.14 | N/A |
| Revenue Next Year | N/A | $300.00 |
| P/E Ratio | ★ N/A | $18.73 |
| Revenue Growth | N/A | ★ 39.24 |
| 52 Week Low | $0.54 | $0.58 |
| 52 Week High | $3.05 | $3.09 |
| Indicator | GPRO | SPRO |
|---|---|---|
| Relative Strength Index (RSI) | 69.55 | 58.04 |
| Support Level | $1.17 | $2.15 |
| Resistance Level | $1.57 | $2.88 |
| Average True Range (ATR) | 0.15 | 0.13 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 78.10 | 64.04 |
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts and accessories, lifestyle gear, applications, and subscriptions and services. The company sells products across the world through retailers, distributors, and on GoPro.com. Its hardware products are designed and developed in the United States, France, China, and Romania, and a majority of the manufacturing is outsourced to contract manufacturers located in China, Thailand, and Vietnam. Geographically, the company generates maximum revenue from the Americas, followed by Europe, Middle East and Africa (EMEA), and Asia and Pacific (APAC) region.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.